Luzhou Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Luzhou Xu has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Di Hu
Tianjin People's Hospital, Tianjin Union Medical Center, Department of Pharmacy, Tianjin, China
1 shared publication - Fang Huang
School of Traditional Chinese Medicine, China Pharmaceutical University, Nanjing, 211199, China
1 shared publication Jun Cheng
Jiangsu Hongdian Research Institute of Traditional Chinese Medicine Industry
1 shared publicationJunlou Liu
The First Clinical Medical College of Nanjing University of Chinese Medicine, Nanjing, China
1 shared publication- Kai Zheng
School of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen 518055, China
1 shared publication - Lei Zhu
Department of Surgery, Emory University School of Medicine, Atlanta, Georgia, USA
1 shared publication
Latest Publications
- 22 March 2021
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 9 (13) , 3068-3078
The design and synthesis of redox-responsive oridonin polymeric prodrug micelle formulation for effective gastric cancer therapy
Advanced gastric cancer (GC) is a significant threat to human health. Oridonin (ORI), isolated from the Chinese herb Rabdosia rubescens, has demonstrated great potential in GC therapy. However, the application of ORI in the clinic was greatly hindered by its poor solubility, low bioavailability, and rapid plasma clearance. Herein, a simple and novel redox-sensitive ORI polymeric prodrug formulation was synthesized by covalently attaching ORI to poly(ethylene glycol)-block-poly(L-lysine) via a disulfide linker, which can self-assemble into micelles (P-ss-ORI) in aqueous solutions and produce low critical micelle concentrations (about 10 mg L−1), characterized by small size (about 80 nm), negative surface charge (about −12 mV), and high drug loading efficiency (18.7%). The in vitro drug release study showed that P-ss-ORI can rapidly and completely release ORI in a glutathione (GSH)-rich environment and under low pH conditions. Moreover, in vitro and in vivo investigations confirmed that P-ss-ORI could remarkably extend the blood circulation time of ORI, enrich in tumor tissue, be effectively endocytosed by GC cancer cells, and quickly and completely release the drug under high intracellular GSH concentrations and low pH conditions, all these characteristics ultimately inhibit the growth of GC. This redox and pH dual-responsive P-ss-ORI formulation provides a useful strategy for GC treatment.
- 22 March 2021
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 9 (13) , 3068-3078
The design and synthesis of redox-responsive oridonin polymeric prodrug micelle formulation for effective gastric cancer therapy
Advanced gastric cancer (GC) is a significant threat to human health. Oridonin (ORI), isolated from the Chinese herb Rabdosia rubescens, has demonstrated great potential in GC therapy. However, the application of ORI in the clinic was greatly hindered by its poor solubility, low bioavailability, and rapid plasma clearance. Herein, a simple and novel redox-sensitive ORI polymeric prodrug formulation was synthesized by covalently attaching ORI to poly(ethylene glycol)-block-poly(L-lysine) via a disulfide linker, which can self-assemble into micelles (P-ss-ORI) in aqueous solutions and produce low critical micelle concentrations (about 10 mg L−1), characterized by small size (about 80 nm), negative surface charge (about −12 mV), and high drug loading efficiency (18.7%). The in vitro drug release study showed that P-ss-ORI can rapidly and completely release ORI in a glutathione (GSH)-rich environment and under low pH conditions. Moreover, in vitro and in vivo investigations confirmed that P-ss-ORI could remarkably extend the blood circulation time of ORI, enrich in tumor tissue, be effectively endocytosed by GC cancer cells, and quickly and completely release the drug under high intracellular GSH concentrations and low pH conditions, all these characteristics ultimately inhibit the growth of GC. This redox and pH dual-responsive P-ss-ORI formulation provides a useful strategy for GC treatment.